Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present UroGen Pharma Ltd. (NASDAQ: URGN).

Full DD Report for URGN

You must become a subscriber to view this report.


Recent News from (NASDAQ: URGN)

UroGen Pharma's (URGN) CEO Ron Bentsur on Q1 2018 Results - Earnings Call Transcript
UroGen Pharma (URGN) Q1 2018 Earnings Conference Call May 15, 2018 8:30 AM ET Executives Catherine Bechtold - Director, Corporate Communications and IR Ron Bentsur - CEO & Director Mark Schoenberg - Chief Medical Officer Gary Titus - CFO & Principal Accounting Officer ...
Source: SeekingAlpha
Date: May, 15 2018 14:15
UroGen Pharma misses by $0.16
UroGen Pharma (NASDAQ: URGN ): Q1 EPS of -$0.88 misses by $0.16 . More news on: UroGen Pharma, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 15 2018 08:03
UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments
Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) to be Presented at American Urological Association (AUA) Annual Meeting on May 21, 2018 Submission of UGN-101 New Drug Application (...
Source: GlobeNewswire
Date: May, 15 2018 08:00
UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018
Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report first quarter 2018 financial results on Tuesday, May 15, 2018, prior to the open of the ...
Source: GlobeNewswire
Date: May, 08 2018 08:00
Factors of Influence in 2018, Key Indicators and Opportunity within Dorman Products, Arch Capital Group, Acacia Communications, UROGEN PHARMA, CyrusOne, and TCP Capital - New Research Emphasizes Economic Growth
NEW YORK, April 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dorman Products, Inc. (NASDAQ:DORM), Arch Capital Group Ltd. (NASDAQ:ACG...
Source: GlobeNewswire
Date: April, 13 2018 07:55
Today's Research Reports on Stocks to Watch: UroGen Pharma and Novartis
NEW YORK, NY / ACCESSWIRE / April 4, 2018 / Shares of Novartis and UroGen both saw gains in Tuesday trading. UroGen saw its shares climb after announcing new data presentation from an interim analysis of an ongoing Phase 3 OLYMPUS trial of its investigational mitomycin formulation. A prosecu...
Source: ACCESSWIRE IA
Date: April, 04 2018 08:00
Midday Gainers / Losers (4/3/2018)
Gainers: MYND +66% . BPTH +33% . EBIO +23% . INNT +22% . ALNA +19% . CASI +19% . SSC +18% . URGN +18% . CLLS +17% . REFR +13% . More news on: MYnd Analytics, Inc., Bio-Path Holdings, Inc., Eleven Biotherapeutics, Inc., Stocks on the move, , Read more .....
Source: SeekingAlpha
Date: April, 03 2018 12:45
UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel(TM)) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)
RA’ANANA, Israel and NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced a new data presentation f...
Source: GlobeNewswire
Date: April, 03 2018 08:31
Institutional Top Ideas Series: Consonance Capital
The last time I did this series was in August of last year, so it has been quite a while. In the past we took a look at portfolios of institutional investors of note, such as BVF, Opaleye, Great Point Partners, Consonance Capital and more. With this reboot, I hope to again delve into the po...
Source: SeekingAlpha
Date: March, 23 2018 13:07
Urogen Pharma's (URGN) CEO Ron Bentsur on Q4 2017 Results - Earnings Call Transcript
Urogen Pharma Ltd (URGN) Q4 2017 Earnings Conference Call March 15, 2018, 08:30 ET Executives Catherine Bechtold - Director, Corporate Communications and IR Ron Bentsur - CEO & Director Mark Schoenberg - Chief Medical Officer Gary Titus - CFO & Principal Accounting Offi...
Source: SeekingAlpha
Date: March, 16 2018 13:25

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1763.9962.0463.9960.25158,282

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1711,26018,29161.5603Short
2018-08-1614,71518,72678.5806Short
2018-08-1517,64429,79459.2200Short
2018-08-1453,63172,71473.7561Short
2018-08-135,00713,96335.8591Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on URGN.


About UroGen Pharma Ltd. (NASDAQ: URGN)

Logo for UroGen Pharma Ltd. (NASDAQ: URGN)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: URGN)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 15 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 25 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 04 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 16 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: March, 15 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 20 2018
      Filing by person(s) reporting owned shares of common stock in a public company >5%
      Filing Type: SC 13DFiling Source: edgar
      Filing Date: February, 15 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 14 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: URGN)

      Daily Technical Chart for (NASDAQ: URGN)


      Stay tuned for daily updates and more on (NASDAQ: URGN)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: URGN)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in URGN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of URGN and does not buy, sell, or trade any shares of URGN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/